β-Blocker use for patients with or at risk for coronary artery disease.

Abstract

Author Affiliations: Department of Otolaryngology, Naval Medical Center Portsmouth, Portsmouth, Virginia (Dr Gallagher); Department of Otolaryngology, Naval Medical Center San Diego, San Diego, California (Dr Brigger); and Department of Pediatric Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston (Dr Hartnick; christopher_hartnick@meei.harvard.edu). Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Hartnick reported serving as a consultant to Gyrus ACMI; receiving a grant from the National Institutes of Health to study voice disorders and voice therapy in children with vocal dysphonia; and receiving book royalties from Springer. Drs Gallagher and Brigger did not report any disclosures. Disclaimer: The views expressed in this letter are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the US government.

DOI: 10.1001/jama.2012.128865

Cite this paper

@article{Rutten2013BlockerUF, title={β-Blocker use for patients with or at risk for coronary artery disease.}, author={Frans Hendrik Rutten and Rolf H. H. Groenwold}, journal={JAMA}, year={2013}, volume={309 5}, pages={438-9} }